<DOC>
	<DOCNO>NCT01545908</DOCNO>
	<brief_summary>Ulcerative colitis condition mainly affect young adult line bowel inflame cause bloody diarrhea . The cause ulcerative colitis unknown treatment remain imperfect cure disease . Initial success show highly novel treatment patient active ulcerative colitis receive fecal enema try replace stool contain bacteria may drive disease healthy donor . To assess work compare well treat disease compare placebo enema .</brief_summary>
	<brief_title>Fecal Biotherapy Induction Remission Active Ulcerative Colitis</brief_title>
	<detailed_description>Hypothesis Fecal biotherapy effective placebo induce remission patient active UC . Approach work plan Patients age 18 active UC define Mayo score ( 13 ) 3 endoscopic score 0 eligible study . Subjects exclude participate another clinical trial , unable give inform consent , severe comorbid medical illness , concomitant Clostridium difficile infection severe UC require hospitalization . Continued treatment 5-ASA , azathioprine , 6-mercaptopurine anti-TNF therapy ( e.g . infliximab ) permit take stable dose equal 12 week prior randomization . Eligible patient randomize receive fecal biotherapy placebo . Fecal biotherapy provide unrelated donor able give inform consent , travel treatment centre St Joseph 's Hospital , Hamilton able collect fecal sample need fecal transplantation protocol . Fecal microbiome profiling carry use Roche 454 pyrosequencing Illumina sequencing . One hundred thirty active UC patient randomize 1:1 accord computer generate randomization list . Randomization administer centrally GI Clinical Trials Unit ensure concealment allocation . Eligible patient randomize receive weekly fecal biotherapy enema placebo enema six week . In order mitigate placebo effect , patient study staff blind allocation treatment . An unblinded , independent laboratory technologist prepare retention enema accord treatment arm patient assign . The enema container fully colour-tinted tip bottom container . The container place inside paper bag , contain bake soda absorb odor . Both patient study nurse require wear tightly fit mask time infusion retention enema . Subjects sigmoidoscopy ( colonoscopy clinically indicate ) , physician assessment complete Mayo score ( 13 ) IBDQ questionnaire ( 15 ) baseline . The physician assessment , IBDQ partial Mayo score ( Mayo score without sigmoidoscopy ) repeat 3 week . A repeat sigmoidoscopy , physician assessment IBDQ Mayo score complete 6 week , exit study . No new medical therapy ( e.g . corticosteroid , antibiotic , probiotic ) permit six-week study period . At end treatment component study , fecal biotherapy offer participant placebo arm clinical sigmoidoscopic evidence active UC .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients age 18 active UC define Mayo score ( 13 ) 3 endoscopic score 0 eligible study Continued treatment 5ASA , azathioprine , 6mercaptopurine antiTNF therapy ( e.g . infliximab ) permit take stable dose equal 12 week prior randomization . Subjects exclude participate another clinical trial , unable give inform consent , severe comorbid medical illness , concomitant Clostridium difficile infection severe UC require hospitalization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Fecal transplant</keyword>
	<keyword>induction remission</keyword>
	<keyword>active ulcerative colitis</keyword>
</DOC>